Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota
Tian Liang, Chongfei Huang, Wenkang Fu, Long Gao, Ningning Mi, Mingzhen Bai, Haidong Ma, Chao Zhang, Ya‐Wen Lu, Jinyu Zhao, Xianzhuo Zhang, Ningzu Jiang, Yanyan Lin, Ping Yue, Jinqiu Yuan, Wenbo Meng
Abstract
Proton pump inhibitors (PPIs) are the most used acid-inhibitory drugs, with a wide range of applications in the treatment of various digestive diseases. However, recently, there has been a growing number of digestive complications linked to PPIs, and several studies have indicated that the intestinal flora play an important role in these complications. Therefore, developing a greater understanding of the role of the gut microbiota in PPI-related digestive diseases is essential. Here, we summarize the current research on the correlation between PPI-related digestive disorders and intestinal flora and establish the altered strains and possible pathogenic mechanisms of the different diseases. We aimed to provide a theoretical basis and reference for the future treatment and prevention of PPI-related digestive complications based on the regulation of the intestinal microbiota.